Portfolio Update

BLACKROCK GREATER EUROPE INVESTMENT TRUST plc All information is at 31 January 2014 and unaudited. Performance at month end with net income reinvested One Three One Three Since launch Month Months Year Years (20 Sep 04) Net asset value (undiluted) -3.4% -2.6% 11.0% 24.0% 187.3% Net asset value (diluted) -2.9% -2.1% 10.3% 26.0% 185.7% Share price 0.4% 0.4% 15.4% 31.5% 189.4% FTSE World Europe ex UK -2.9% -3.0% 11.1% 18.7% 125.2% Sources: BlackRock and Datastream At month end Net asset value (capital only): 241.35p Net asset value (including income): 241.52p Net asset value (capital only)*: 240.00p Net asset value (including income)*: 240.13p Share price: 242.00p Premium to NAV (including income): 0.2% Premium to NAV (including income)*: 0.8% Subscription share price: 27.88p Gearing: 2.8% Net yield**: 1.9% Total assets (including income): £265.5m Ordinary shares in issue: 106,963,851*** Subscription shares in issue 22,312,055 * Diluted for subscription shares and treasury shares. ** Based on an ordinary dividend of 4.5p per share (excluding a special dividend of 1.0p) for the year ended 31 August 2013. *** Excluding 5,629,676 shares held in treasury. Benchmark Sector Analysis Total Assets (%) Index (%) Country Analysis Total Assets (%) Financials 31.0 23.5 Switzerland 19.8 Health Care 15.9 11.9 France 18.5 Industrials 14.1 14.5 Germany 16.8 Consumer Goods 13.7 17.4 Netherlands 13.8 Consumer Services 12.5 5.4 Denmark 6.4 Technology 4.3 3.8 Sweden 6.1 Basic Materials 3.8 8.5 Belgium 4.1 Utilities 1.9 3.9 Russia 3.3 Telecommunications 1.9 4.3 Turkey 2.8 Oil & Gas 1.5 6.8 Spain 2.4 Net current liabilities (0.6) - Italy 2.2 ----- ----- Ireland 2.0 100.0 100.0 Portugal 1.3 ===== ===== Hungary 1.1 Net current liabilities (0.6) ----- 100.0 ===== Ten Largest Equity Investments (in alphabetical order) Company Adecco Switzerland Airbus Netherlands Bayer Germany ING Netherlands Novo Nordisk Denmark Roche Switzerland Sanofi France Société Générale France Swiss Re Switzerland Zurich Insurance Switzerland Commenting on the markets, Vincent Devlin, representing the Investment Manager noted: During the month, the Company's NAV fell by 3.4% and the share price gained 0.4%. For reference, the FTSE World Europe ex UK Index lost 2.9% during the same period. European equities began 2014 with a negative return. Domestically, data for the Euro area continued to improve, with the January flash composite PMI rising by 1.1 points to 53.2 and the Citi Euro area surprise index reaching the highest level since October. However, this improvement was overshadowed by concerns emanating from emerging markets, specifically Turkey and South Africa, as the imbalances, reflected in significant current account deficits, came to a head. The Euro also continued to appreciate against the dollar during the month and large cap stocks underperformed small and mid-caps, which tend to have less global exposure. Interestingly, at a country level, Southern European countries outperformed the broad market, with stock markets in Portugal, Italy, Spain and Greece all posting positive returns during January. Stock selection was the main driver of the negative returns during the month, while sector allocation contributed to returns. From a sector perspective, the Company's underweight positions to oil & gas and basic materials proved profitable, as did an overweight position in the financial sector, although an underweight in the consumer services sector was less successful. Stock selection within the financial sector was the Company's largest detractor and the main driver of the negative return. At a stock level, positions in Turkish and Russian banks Garanti Bankasi, Sberbank and Halk Banka were the Company's worst performing stocks, falling on emerging market fears. Russian technology company Yandex, Portuguese food retailer Jeronimo Martins and French spirit producer Remy Cointreau, all underperformed due to the high level of emerging market exposure. On the positive, a position in Danish insulin manufacturer Novo Nordisk benefited from the delay in a competitors drug which would be launched in the same market as one of its key pipeline drugs. Renault also performed well after it saw strong Q4 volume growth across geographies. Holdings in select banks including Commerzbank, KBC and UBS continued to perform well, as did a position in Danish jewellery manufacturer Pandora. At the end of the month, the Company was positioned with higher weightings in consumer services, financials, health care and technology and with lower weightings in basic materials, oil & gas, industrials, utilities, consumer goods and telecoms. Outlook The outlook for Europe looks more positive than it has done since the financial crisis began. Economic conditions are showing signs of improvement, public policy and political uncertainties have eased, and the Eurozone has passed the peak of austerity measures. We forecast a global synchronised economic recovery in 2014 with developed markets driving growth, albeit from a low starting base. As mentioned before, we now need to see evidence of corporate profit growth. Given the economic scenario painted above, lower labour and input costs, combined with supportive economic momentum, should provide the impetus much needed following a prolonged period of falling profits. We expect equity markets to provide a total return of 10-12% this year given the potential for positive earnings surprise, valuation and dividend attractions and investors' appetite still remaining supportive for European Equities. However, it is worth reminding ourselves that there is risk surrounding any scenario. The recovery in Europe remains fragile and while much progress has been made in unifying the banking system, banking stress tests and lack of credit may hinder economic recovery. Policy error could also add to disappointment and we are cognisant of the impact US tapering may have on economies and currencies which could subsequently lead to increased volatility. Any significant disappointment would cause us to revise our scenario. 14 February 2014 ENDS Latest information is available by typing www.brgeplc.co.uk on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager's website nor the contents of any website accessible from hyperlinks on the Manager's website (or any other website) is incorporated into, or forms part of, this announcement.
UK 100

Latest directors dealings